Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
Sotio Biotech Inc.
Stanford University
FindCure Biosciences (ZhongShan) Co., Ltd.
Kaiser Permanente
University of Colorado, Denver
University of Nebraska
Adela, Inc
Eli Lilly and Company
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Columbia University
Theratechnologies
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Universidade Federal de Pernambuco
Taproot Health
University of Modena and Reggio Emilia
VitaMed Research LLC
Salubris Biotherapeutics Inc
NantCell, Inc.
TransThera Sciences (Nanjing), Inc.
Beijing Friendship Hospital
Istituti Clinici Scientifici Maugeri SpA
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University Medical Center Groningen
Hoffmann-La Roche
Stanford University
Kineta Inc.
Institut Bergonié